Followers | 43 |
Posts | 4253 |
Boards Moderated | 0 |
Alias Born | 07/14/2010 |
Wednesday, April 14, 2021 11:43:10 AM
Profitability
Profit Margin 0.00%
Operating Margin (ttm) -300.79%
Management Effectiveness
Return on Assets (ttm) -20.00%
Return on Equity (ttm) -61.68%
Income Statement
Revenue (ttm) 6.35M
Revenue Per Share (ttm) 0.14
Quarterly Revenue Growth (yoy) -76.90%
Gross Profit (ttm) -6.66M
EBITDA -17.07M
Net Income Avi to Common (ttm) -27.36M
Diluted EPS (ttm) -0.4500
Total Debt (mrq) 9.75M
Book Value Per Share (mrq) 0.94
Cash Flow Statement
Operating Cash Flow (ttm) -14.67M
Levered Free Cash Flow (ttm) -7.67M
Recent IMMP News
- Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B • GlobeNewswire Inc. • 04/24/2024 12:00:00 PM
- Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761 • GlobeNewswire Inc. • 04/18/2024 12:00:00 PM
- Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer • GlobeNewswire Inc. • 04/17/2024 12:00:00 PM
- Immutep Announces First Clinical Data from 90mg Dosing of Efti • GlobeNewswire Inc. • 03/05/2024 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/30/2024 09:01:56 PM
- Immutep Quarterly Activities Report Q2 FY24 • GlobeNewswire Inc. • 01/30/2024 01:00:00 PM
- First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer • GlobeNewswire Inc. • 01/04/2024 01:00:00 PM
- Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer • GlobeNewswire Inc. • 12/21/2023 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/21/2023 11:06:56 AM
- Immutep Receives A$2.6 million R&D Tax Incentive from French Government • GlobeNewswire Inc. • 12/07/2023 01:00:00 PM
- Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial • GlobeNewswire Inc. • 11/22/2023 01:00:00 PM
- Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma • GlobeNewswire Inc. • 11/09/2023 01:00:00 PM
- Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer • GlobeNewswire Inc. • 11/06/2023 01:00:00 PM
- Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer • GlobeNewswire Inc. • 11/03/2023 04:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/03/2023 10:06:58 AM
- Immutep to Participate in November Investor Events • GlobeNewswire Inc. • 11/02/2023 12:00:00 PM
- Immutep Quarterly Activities Report Q1 FY24 • GlobeNewswire Inc. • 10/31/2023 12:00:00 PM
- Immutep receives ~A$1.13 million R&D Tax Incentive • GlobeNewswire Inc. • 10/25/2023 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/25/2023 10:07:25 AM
- Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023 • GlobeNewswire Inc. • 10/24/2023 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/24/2023 10:35:30 AM
- Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer • GlobeNewswire Inc. • 10/23/2023 12:00:00 PM
- Immutep Announces Publication of Abstracts at ESMO Congress 2023 • GlobeNewswire Inc. • 10/16/2023 12:00:00 PM
- Immutep Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting • GlobeNewswire Inc. • 10/03/2023 12:00:00 PM
- Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use • GlobeNewswire Inc. • 09/21/2023 12:00:00 PM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM